Compare Regeneron Pharmaceuticals Inc (REGN) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Sony Group Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $740.02 (market cap $76.14B), while Sony Group Corp trades at $24.07 (market cap $136.87B). The key difference: Sony Group Corp is the larger of the two by market cap, and Sony Group Corp pays the higher dividend (0.66%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Sony Group Corp for 96 Days on average.
| REGN | SONY | |
|---|---|---|
Market Cap | $76.14B | $136.87B |
Volume | 500,239 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $852.03 | $30.26 |
52-Week Low | $557.73 | $19.32 |
Typical Hold Time | 107 Days | 96 Days |
Enterprise Value | $70.85B | $134.77B |
Dividend Yield | 0.51% | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Sony trades at $23.52, down 1.38% on the day, with mixed technical signals showing a neutral overall trend. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with solid gross margins of 31.82%, though net income margin turned negative at -1.75% for 2026. Analyst sentiment remains bullish with 11 buy ratings versus 5 holds.
Sony presents a compelling value case with reasonable valuation multiples (P/E 19.93, P/S 1.75) and strong cash flow generation. However, recent negative profitability metrics and the Q1 2026 earnings miss highlight execution risks. The company's diversified entertainment portfolio and AI positioning offer growth potential, but investors should monitor margin recovery and content performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
